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 25 
Abstract 26 
This narrative review compares evidence from experimental, epidemiological and 27 
clinical studies of the health benefits of rapeseed (Canola) oil and olive oil in order to 28 
assess if rapeseed oil is suitable as a sustainable alternative to olive oil as part of a 29 
Mediterranean-style diet in countries where olive trees do not grow. From 30 
epidemiological studies, the evidence for cardiovascular protection by extra virgin 31 
olive oil is "convincing", and for cancers "limited-suggestive", especially oestrogen 32 
receptor negative breast cancer, but more studies are required in relation to cognitive 33 
impairment. Evidence for rapeseed oil is limited to short term studies on biomarker 34 
risk factors for cardiovascular disease. Any benefits of rapeseed oil are likely to be due 35 
to α-linolenic acid, but this is prone to oxidation during frying. We conclude that due 36 
to a lack of evidence from observational or intervention studies indicating that 37 
rapeseed oil has comparable health benefits to extra virgin olive oil, rapeseed oil 38 
cannot currently be recommended as a suitable substitute for extra virgin olive oil as 39 
part of a Mediterranean-style diet.  40 
 41 
Abbreviations 42 
MD   Mediterranean diet 43 
EVOO  extra virgin olive oil  44 
OO   either virgin or non-virgin olive oil (not specified) 45 
RO   rapeseed (Canola) oil 46 
ALA    α-linolenic acid  47 
TFA   trans fatty acid 48 
UFA   unsaturated fatty acid 49 
 50 
Introduction 51 
The traditional Mediterranean diet (MD) is widely recognised as one of the healthiest 52 
in the world, and it is likely that more widespread adoption of this diet in non-53 
Mediterranean countries would lead to a significant reduction in the incidence of many 54 
chronic diseases(1). Some health organisations in non-Mediterranean countries now 55 
recommend a MD. For example, in the UK a MD is recommended by NICE (National 56 
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Institute for Health and Care Excellence) for secondary prevention following a 57 
myocardial infarction(2). However, despite this type of targeted advice, there is only 58 
limited promotion of a MD to the general population in non-Mediterranean countries(3), 59 
and campaigns for healthy eating tend to focus on promoting diets that are compatible 60 
with the cultural heritage of a people. For example, Public Health England promotes 61 
the Eatwell Plate - a dietary pattern modelled on a healthy UK-based diet(4), and in 62 
Norway the traditional Norwegian diet has been promoted as being more appropriate 63 
for this country than adopting a MD(5).  64 
 65 
Nevertheless, it can be argued that the well-proven health benefits of the MD justify it 66 
being more widely promoted in non-Mediterranean countries. Promoting a MD in non-67 
Mediterranean countries is a viable public health approach since there is usually good 68 
compliance to this diet by individuals in non-Mediterranean countries who adopt it, 69 
and, in general, eating habits in many countries are becoming more flexible(6, 7). In 70 
addition, local produce can be used, rather than foods that only grow in Mediterranean 71 
countries, since food choices for a MD are mostly based on food groups, such as 72 
"fruits" or "vegetables", rather than on specific foods(8). Indeed, it has been argued that 73 
many features of recommended dietary patterns in Northern Europe, such as high 74 
consumption of fruit and vegetables and low consumption of meat, are quite similar to 75 
the MD(9).  76 
 77 
One exception to the generalised recommendation of food groups, rather than specific 78 
foods, is to consume olive oil (OO) as the main source of added fat. Indeed, it is the 79 
consumption of OO - more than any other single factor - that distinguishes the 80 
traditional MD from other dietary patterns(10). However, adopting OO as the main 81 
dietary fat as part of a MD in non-Mediterranean populations may present an obstacle 82 
since it is relatively costly compared with other cooking oils, and consumption of OO 83 
in non-Mediterranean populations is low(11). Consuming large quantities of OO in non-84 
Mediterranean countries also raises issues of food security. The food security agenda 85 
aims to increase production of foods within national borders in order to guarantee food 86 
production independent of international influences. Since olive trees only grow in 87 
Mediterranean type climates this may not be compatible with food security issues, 88 
although this is less of an issue between EU countries which share interdependent 89 
policies.  90 
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 91 
The health benefits of OO are attributed both to its high content of the MUFA oleic 92 
acid(12) and to various minor components(13). Rapeseed oil (RO) (known as Canola oil 93 
in the US, Canada and some other countries) is a potential substitute for OO since it 94 
has a similar MUFA content to OO and its overall fatty acid profile is favourable due 95 
to a low content of SFA and high content of PUFA, including α-linolenic acid (ALA). 96 
Consumption of RO is now high in many non-Mediterranean countries, partly due to 97 
low cost, and also because it is perceived as being a healthy oil.  There is increasing 98 
substitution of RO for OO, such as in recipes for the home cook, and in the UK NICE 99 
do not specify OO in their description of a MD but instead refer to "vegetable oil" - 100 
which in the UK generally refers to RO(2). Hence, perhaps not surprisingly, 101 
consumption of RO in the UK may now be starting to displace that of OO since OO 102 
sales have seen their first fall in over 20 years(14).  103 
 104 
Rapeseeds are widely grown - both for biofuel and for human consumption - in many 105 
EU countries, Canada, China, Australia and India(15). In the UK, rapeseeds are the only 106 
oilseeds harvested in significant quantities. In view of the relatively low cost and the 107 
ready availability of RO, we examine if the health benefits of RO justify it replacing 108 
OO as part of wider recommendations for consumption of a MD in non-Mediterranean 109 
countries, and so ask if RO can be regarded as an ersatz "Northern OO" for the 110 
domestic consumer.  111 
 112 
Methods 113 
We used a narrative review approach, and searched electronic databases PubMed and 114 
Scopus up until April 2014. Key words "olive oil", "virgin olive oil", "rapeseed oil" 115 
and "Canola" were used in combination with keywords "composition" (and related 116 
words such as "phenolics", "antioxidants"), "cardiovascular disease" (and related words 117 
such as "coronary heart disease" and "myocardial infarction"), "cancer" and 118 
"neurodegenerative disease" (and related words such as "Alzheimer's disease" and 119 
"dementia") and the study method (such as "cohort" and "meta analysis"). 120 
 121 
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Composition 122 
Fats 123 
As well as a high MUFA content (mainly oleic acid), OO also contains a range of other 124 
FAs(16). Levels of the various FAs in OO vary quite widely between oils depending on 125 
factors such as the type of olive tree cultivar used for oil production (see Table 1). RO 126 
also has a high MUFA content, as well as considerably higher levels of ALA than OO 127 
(see Table 1). Consumption of ALA is linked to cardioprotective benefits (see below). 128 
However, RO also contains approx. 1% trans isomers of ALA, which are produced 129 
during the deodorisation step of oil production(17, 18). There is a well-established link 130 
between trans fatty acid (TFA) consumption and increased risk of CHD(19) and 131 
although the level in RO does not in itself constitute a health risk, it is desirable to keep 132 
levels of TFA to a minimum. 133 
 134 
RO is very low in SFAs, comprising only approx. 6% of total FAs. This is about half 135 
the average content of SFA in OO, and it has been argued that this gives RO an 136 
advantage over OO(20). However, the quite low proportion of SFA even in OO means 137 
that it would not normally be a significant daily source of SFA compared to other 138 
dietary sources such as meat or dairy produce. For example, 20 ml OO contains 128 139 
mg SFA giving 9.62 kJ (2.3 kcal) as SFA. Current UK intake of SFA is 12.7 % of total 140 
energy intake(21). Hence, consumption of 20 ml OO represents less than 1% of the 141 
average daily intake of energy in the UK from SFA (0.9% total calories in women 142 
based on an intake of 8368 kJ (2000 kcal) and 0.7% in men based on an intake of 143 
10460 kJ (2500 kcal)).  144 
 145 
Minor components 146 
There are significant differences between the minor components in RO and extra virgin 147 
olive oil (EVOO), due not only to the source of the oil but also to production methods. 148 
EVOO is produced using mild conditions that include pressing olive fruits at low 149 
temperature, washing with water, filtration and centrifugation. These conditions retain 150 
many of the original components of the olives. The most abundant minor component is 151 
the hydrocarbon squalene, and there are smaller quantities of carotenoids, triterpenoids, 152 
phytosterols (eg β-sitosterol, Δ5-avenasterol and campesterol) and tocopherols (approx. 153 
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95% α-tocopherol) (Table 1). EVOO also contains a wide variety of phenolic 154 
compounds including secoiridoids (eg oleuropein) and their phenolic derivatives (eg 155 
tyrosol, hydroxytyrosol), flavonoids (eg luteolin, apigenin), and lignans (pinoresinol 156 
and acetoxypinoresinol). EVOO is the best quality OO and must meet predefined 157 
criteria in terms of sensory qualities and limits of acidity. Other OOs have substantially 158 
lower levels of most of the minor components, and phenolic compounds in particular 159 
are reduced(16). 160 
 161 
Many potentially beneficial biological actions have been described for the minor 162 
components in EVOO. EVOO phenolics reduce markers for inflammation and 163 
oxidative stress in vitro and in vivo(22, 23). Squalene reduces oxidative stress in human 164 
mammary epithelial cells(24). Lignans are phytoestrogens with possible anticancer 165 
activity(25), and it is noteworthy that OO (both EVOO and other OO) was found to be 166 
the major dietary source of lignans in participants in the PREDIMED study(26). 167 
Secoiridoids such as oleuropein and its derivatives are of particular interest in relation 168 
to the health properties of EVOO since they are not found in other food plants. 169 
 170 
Standard production of RO requires a far higher level of processing including solvent 171 
extraction of the oil from the pressed seeds, and refining by degumming, 172 
neutralization, bleaching and deodorization. As a consequence, most of the minor 173 
constituents that were originally present in the rapeseeds are significantly depleted in 174 
the oil. Some of the phytosterols (which include β-sitosterol, campesterol and 175 
brassicasterol) and tocopherols (mainly α- and γ-tocopherol, in a ratio of approx. 1:2) 176 
are lost, as are most or all of the phenolics originally present (which includes a high 177 
proportion of sinapic acid and its derivatives)(27). Phytosterols are best know for their 178 
ability to reduce cholesterol uptake from the gut, although some, such as Δ5-179 
avenasterol, possess antioxidant activity. 180 
 181 
Cooking 182 
Consumption of raw EVOO is often quite high in Mediterranean cuisine, and this may 183 
be important since compositional changes can occur to oils during cooking (see 184 
below). Raw EVOO is used as a salad dressing or simply poured on bread, as a main 185 
ingredient in many dips and sauces and as an addition to stews at the end of cooking to 186 
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enhance flavour. Whereas some people prize EVOO for its flavour, it is unclear if the 187 
flavour of raw RO would be an acceptable substitute. OO is also consumed after frying 188 
and baking due to oil being absorbed into the cooked food. Large quantities of OO are 189 
consumed in the lathera dishes of some eastern Mediterranean countries since the 190 
cooking oil in which vegetables are cooked is consumed as an integral part of the dish. 191 
OO is more commonly used for shallow frying (which typically requires an oil 192 
temperature of 140-160°C) rather than deep-frying (180-190°C) due to its relatively 193 
low smoke point.  194 
 195 
There can be significant thermal degradation of fatty acids and minor components in 196 
oils during cooking, and this may potentially have detrimental health effects. 197 
Undesirable changes include the hydrolysis and polymerisation of triglycerides, 198 
oxidation of fatty acids and sterols, and generation of TFAs. Lipid oxidation is 199 
influenced by various factors such as the type of food present, the proportion of oil 200 
exposed to the air, and the amount of unsaturated fats (UFA) in the oil. Oxidation 201 
increases with the degree of unsaturation: ALA (18 : 3n-3) is 2.4 times more reactive 202 
than linoleic acid (18 : 2n-6) which is 40 times more reactive than oleic acid (18 : 1n-203 
9)(28). This is of potential concern for RO due to its high ALA content. Prolonged and 204 
repeated deep frying with RO, as may occur in commercial establishments, can also 205 
lead to the generation of quite high levels of TFAs(29).  206 
 207 
Loss of antioxidants 208 
During frying, antioxidants in oils are lost due both to direct thermal degradation and 209 
by acting as antioxidants and so being consumed during the thermal oxidation of 210 
unsaturated fats(30). EVOO contains a favourable ratio of antioxidants to PUFAs 211 
compared to other types of oils, and this reduces both the rate at which antioxidants are 212 
lost and the rate of lipid oxidation that occurs during frying(31, 32). Antioxidants in 213 
EVOO deplete at different rates, as demonstrated in a study by Gomez-Alonso et al 214 
who found that hydroxytyrosol was depleted to a far greater extent than tyrosol when 215 
EVOO was used for frying potatoes at 180°C for 10 min(33). Phenolics in EVOO help 216 
stabilise vitamin E during heating and vitamin E in turn helps protect PUFAs from 217 
oxidative degradation(31).  218 
 219 
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Despite losses of minor components due to frying, heated virgin OO (VOO) has been 220 
shown to retain beneficial effects on postprandial inflammation. VOO repeatedly 221 
heated to 180°C suppressed postprandial inflammation in obese subjects (determined 222 
as NFκB activation in peripheral blood monocytes) compared to a seed oil with similar 223 
fat content  (a blend of high oleic acid sunflower oil and RO)(34). Although the heating 224 
protocol completely depleted hydroxytyrosol in the VOO, other minor components, 225 
including some phenolics, were retained.  226 
 227 
In summary, although antioxidants in EVOO are reduced during frying, using EVOO 228 
rather than other types of OO for frying may be justified as a means to minimise 229 
oxidation of the relatively low content of PUFAs and to reduce postprandial 230 
inflammation. Antioxidants in EVOO have also been to shown to migrate into the food 231 
during cooking and so may confer health benefits in the body(35, 36).  232 
 233 
Antioxidants in RO include phytosterols, vitamin E and Coenzyme Q, although levels 234 
of phenolics are very low compared to EVOO (see Table 1). Vitamin E content was 235 
reduced by two-thirds when RO was heated at 150°C for 6 h(30), and vitamin E was 236 
also significantly depleted using conditions designed to replicate RO being used for 237 
deep frying(37). The concentration of ALA in RO is a major determinant of the extent 238 
of fatty acid oxidation(38).  The relatively low ratio of antioxidants to PUFAs in RO 239 
may lead to significant losses of antioxidants and increase lipid peroxidation, although 240 
this will depend on the time period and temperature used for frying. The more 241 
favourable balance between antioxidants and PUFAs in EVOO may retain more 242 
antioxidants. 243 
 244 
Generation of toxic compounds 245 
Insufficient protection of PUFAs from oxidation leads to their conversion to 246 
hydroperoxides and these may break down to various volatile compounds(39). Some, 247 
like acetaldehyde and acrolein (2-propenal), are toxic. Acetaldehyde is classified as a 248 
carcinogen by the EU, whereas the main health effect of exposure to acrolein is 249 
irritation of the eyes, the mucosae and the skin(40). It is therefore desirable to minimise 250 
exposure of the cook to toxic volatile compounds produced during frying. Fullana et al 251 
reported that acetaldehyde production at 180°C was twice as high for RO compared 252 
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with either OO or VOO(41), although levels from all oils were low, and no acetaldehyde 253 
emissions were detected by Katragadda et al at 180°C(42). Production of acrolein by RO 254 
at 180°C was found to be approximately five times higher than acrolein production by 255 
either EVOO or OO(41, 42). This is probably due to the high ALA content of RO since 256 
recent studies indicate that thermal degradation of ALA is the main source of acrolein 257 
in RO(43, 44). The presence of antioxidants in EVOO such as chlorophylls, pheophytins 258 
and carotenoids, may also reduce acrolein formation compared with RO(45). Despite the 259 
generation of some toxic volatiles, especially by RO, there is no evidence that, under 260 
normal domestic conditions, using fresh RO for shallow frying is likely to pose a 261 
health risk through inhalation.  262 
 263 
In summary, there exists a clear advantage for EVOO over RO in terms of the former's 264 
richer composition, limited processing without solvent extraction and deodorization, 265 
and safety of use in cooking. 266 
 267 
Health  268 
Various studies have assessed the health benefits of OO and RO. Several expert 269 
committees have described the basis for making a robust judgement of a causal 270 
relationship between a nutrient or food and disease risk(46, 47). Consistency between 271 
several observational studies is necessary, with prospective studies favoured over case-272 
control studies. When available, there should be randomized controlled trials (RCT) of 273 
sufficient size and duration, with more weight being given to disease incidence as an 274 
endpoint rather than to biological markers. Experimental studies, both in vivo and in 275 
vitro, can provide biological plausibility. We follow these guidelines for assessing the 276 
respective health benefits of OO and RO. Epidemiological studies are summarised in 277 
Tables 2 and 3. 278 
 279 
OO and health 280 
Cardiovascular diseases 281 
Many epidemiological studies, including RCT, have shown that a Mediterranean 282 
dietary pattern that includes OO is convincingly associated with a reduced risk of 283 
CVD, and is probably associated with a reduced risk of certain cancers and 284 
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neurodegenerative diseases (reviewed in(48)). Only a few of these epidemiological 285 
studies have focused on the specific effect of OO. Ancel Keys, the pioneer advocate of 286 
the MD, first proposed that it was the ratio of MUFA:SFA that was the key component 287 
for the health benefits of the MD(49). Although this suggested that the importance of 288 
OO was to provide MUFA, later on it was established that MUFA from sources other 289 
than OO (animal fat contains 40 to 45 % of MUFA) did not have the same beneficial 290 
effect(50).  291 
 292 
Consequently, studies were undertaken to decipher the specific effect of OO. In the 293 
Three-City Study, those with intensive use of OO showed a lower risk of stroke 294 
compared to those who never used OO(51). In the Italian-EPIC cohort, women with a 295 
high OO consumption had reduced incidence risk of non-fatal and fatal myocardial 296 
infarction(52), although it should be noted that this study has been criticised because it 297 
was not fully adjusted. In another analysis conducted on the EPIC population in Spain, 298 
a high intake of OO decreased the risk of overall mortality by 26% and of CVD deaths 299 
by 44%(53). A recent meta analysis by Martinez-Gonzalez et al comparing high versus 300 
low intake of OO found a significant risk reduction for stroke, but the risk reduction 301 
for CHD was not significant (Table 2)(54).  302 
 303 
In the studies included in the meta analysis by Martinez-Gonzalez et al, only that by 304 
Buckland et al distinguished between OO and EVOO. In this well-conducted study 305 
from Spain, there was a reduction of CVD incidence of 7% for each 10g increase of 306 
OO per 8.4 MJ ingested, and this effect was greater for EVOO (risk reduction 14%)(55). 307 
The role of EVOO was examined in the PREDIMED randomised control trial. 308 
Participants at high vascular risk were randomly allocated to three groups. Two groups 309 
received a typical MD supplemented with either EVOO (1 litre/week) or mixed nuts 310 
(30 g/day). The third, control group was advised to follow a low-fat diet. In the two 311 
groups that received advice on the MD, the risk of CVD (myocardial infarction, stroke 312 
or death from cardiovascular disease) was reduced by approximately 30%(56). Recent 313 
additional analysis of the PREDIMED study provides further evidence for a superior 314 
benefit for EVOO versus non-virgin OO in CVD risk. This observational prospective 315 
cohort analysis was based on baseline consumption of OO ie prior to randomisation 316 
into groups. In individuals at high cardiovascular risk, there was a statistically 317 
significant reduction in total cardiovascular risk and stroke (but not myocardial 318 
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infarction) for total OO consumption or for consumption of EVOO, but not for 319 
consumption of non-virgin OO(57) (see Table 2). These results remained even after 320 
adjusting for adherence to a MD. The results highlight the possible important 321 
contribution of minor components in EVOO for cardiovascular protection. 322 
 323 
Short-term studies with cardiovascular risk factors as end-points also suggest that 324 
phenolics are important for the cardiovascular benefits of VOO. For example, the 325 
EUROLIVE study, comparing OO high and low in phenolics, found a linear increase 326 
in HDL cholesterol levels for low-, medium-, and high-polyphenol olive oils, and a 327 
linear decrease in oxidized LDL levels(58). A reduction in LDL oxidation for EVOO 328 
with a minimum hydroxytyrosol content is the basis for a recent health claim issued by 329 
the European Food Safety Authority for the health benefits of OO(59). VOO, as part of a 330 
Med diet, has also been shown to reduce levels of circulating inflammatory molecules 331 
associated with increased cardiovascular risk(60).  332 
 333 
Experimental models in vitro and in vivo suggest that VOO can  favourably alter many 334 
stages in atherosclerosis. VOO was shown to reduce atherosclerosis  in apo-E deficient 335 
mice and hamsters(61). Anti-inflammatory activities of minor components in VOO 336 
include reducing prostacyclin synthesis in human vascular smooth muscle cells, 337 
inhibiting cyclo-oxygenases(62), and inhibiting endothelial adhesion molecule 338 
expression(63). Phenolics also have favourable effects on haemostasis(64)   339 
 340 
Although many studies indicate that cardiovascular risk is reduced when MUFA 341 
replaces dietary SFA or carbohydrates(65), epidemiological evidence for a specific role 342 
for the oleic acid in OO for cardiovascular protection is limited. However,  short term 343 
feeding studies in humans suggest that one benefit of diets rich in OO is that they do 344 
not have the adverse effects on post-prandial inflammation and haemostasis seen with 345 
diets rich in SFA(12). OO also has beneficial hypotensive effects in short term feeding 346 
studies(12), and oleic acid is implicated in these effects since, in rat models, triolein (the 347 
main TAG in OO, consisting of 3 oleic acid moieties) reduced blood pressure as 348 
effectively as VOO(66).  349 
 350 
Cancers 351 
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A beneficial effect of adherence to a MD (as assessed by a Mediterranean diet score) 352 
and reduced cancer risk is found to be greater in Mediterranean, rather than non-353 
Mediterranean, populations(8). The overall cancer mortality in the Spanish study quoted 354 
above showed a RR <1 but was non significant(53). In the PREDIMED study, no 355 
statistically significant associations were found for consumption of any type of OO and 356 
mortality from all types of cancer(54). However, different cancer sites are characterized 357 
by different risk factors and for some types of cancer there are indications of a specific 358 
effect of OO, and this is supported by several in vitro and in vivo experimental 359 
studies(67).  A meta-analysis of 25 studies reported risk reduction for upper digestive 360 
and respiratory tract cancers, breast and, possibly, colorectal and other cancer sites(68). 361 
Similarly, a posteriori dietary pattern analysis has demonstrated a greater risk 362 
reduction in breast cancer when OO was present in the pattern(69-71). A more recent 363 
study addressed the question of OO and breast cancer in the Mediterranean countries of 364 
the EPIC study and observed a non-significant risk reduction for oestrogen receptor 365 
negative (ER-) progesterone receptor negative (PR-) breast cancers with a high OO 366 
intake(72). These cancers are independent from hormonal factors and differ from ER+ 367 
breast cancers in terms of risk factors. However, they represent only 25 to 30% of all 368 
breast cancers and the lack of statistical power might explain the large CI seen in this 369 
study (see Table 2). This epidemiological observation is supported by an experimental 370 
model showing that the OO phytochemical oleuropein is more cytotoxic for basal-like 371 
ER- MDA-MB-231 cells than for luminal ER+ MCF-7 cells(73).  372 
  373 
Neuro-degenerative diseases 374 
In the prospective Three City Study, OO was associated with a decrease in cognitive 375 
impairment(74). In participants of the PREDIMED study, consumption of some foods 376 
was independently associated with better cognitive function. Among them, total OO 377 
positively correlated with immediate verbal memory and EVOO with delayed verbal 378 
memory(75). More recently, in the PREDIMED-Navarra trial, 285 participants at high 379 
vascular risk were randomly allocated to three groups: a MD supplemented with 380 
EVOO, a MD supplemented with mixed nuts, a low-fat diet. Lower mild cognitive 381 
impairment was observed in the EVOO group compared to the control group(76). 382 
Participants assigned to the MD + nuts group did not differ from controls. Various anti-383 
oxidant and anti-inflammatory phenolics in EVOO may contribute to these beneficial 384 
effects since oxidative stress and inflammation are associated with neuro-385 
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degeneration(77). More specific effects have also been described for EVOO phenolics. 386 
Tyrosol and hydroxytyrosol have been shown to decrease activation by β amyloid (Aβ) 387 
of the pro-inflammatory transcription factor NFκB in cultured neuroblastoma cells(78). 388 
In mouse models of Alzheimer's disease where there is increased Aβ, the EVOO 389 
phenolics oleocanthal and oleuropein reduced Aβ levels and plaque deposits(79, 80) and 390 
improved memory(81). 391 
  392 
The severity of skin photo-aging was significantly attenuated by the consumption of 393 
MUFA from OO in subjects of the SUVIMAX cohort(82). Only MUFA from OO was 394 
efficient, suggesting that phenolics or squalene in OO might be responsible for the 395 
beneficial effect on skin photo-aging. 396 
 397 
In summary, based on recognised criteria of evidence in human studies, the level of 398 
evidence for the relationship of EVOO with CVD can be qualified as "convincing", 399 
and for cancers as "limited-suggestive", especially ER- breast cancer. For aging and 400 
cognitive impairment, fewer data exist in favour of a specific beneficial effect of OO, 401 
and require confirmation. There is good evidence from both human and experimental 402 
studies that phenolics present in EVOO are important for the cardiovascular benefits. 403 
More limited experimental studies also suggest that phenolics are important for the 404 
anti-cancer and neuro-protective effects of EVOO.  405 
 406 
RO and health 407 
Whereas many studies have examined the relationship of OO with disease incidence or 408 
mortality as well as biomarkers for disease, studies with RO are mainly limited to 409 
outcomes based on biomarkers. Two recent reviews received funding from the food 410 
industry and the RO industry(83, 84), hence leading to possible conflicts of interest(85, 86). 411 
Most studies with RO have used raw RO. This limits the interpretation of these studies 412 
since most RO is consumed after frying and this can cause significant changes in 413 
composition, especially of ALA, as discussed above.  414 
 415 
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Cardiovascular disease 416 
A number of reports comparing RO with a source of SFA on biomarkers of CVD risk 417 
(total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides, lipid 418 
peroxidation and inflammatory biomarkers) have found that RO is relatively beneficial, 419 
as it is an oil low in SFA and high in MUFA+PUFA(84). As the U.S. Food and Drug 420 
Administration put it in the qualified health claim for canola (rapeseed) oil in 2006: 421 
“Limited and not conclusive scientific evidence suggests that eating about 1.5 422 
tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart 423 
disease due to the unsaturated fat content in canola oil. To achieve this possible 424 
benefit, canola oil is to replace a similar amount of saturated fat and not increase the 425 
total number of calories you eat in a day.”(87) 426 
 427 
It is the generally accepted view that the benefits to heart health are greater when SFA 428 
is replaced with PUFA, rather than when SFA is substituted with MUFA(50). Since 429 
there are no observational studies with RO, a review of epidemiological studies of the 430 
specific effect of ALA is relevant, albeit with the proviso of possible changes due to 431 
frying. These are summarised in Table 3. A review by the Afssa expert group in 2008 432 
concluded that results on mortality were inconsistent(88). Whereas Folsom et al 2004 433 
observed a modest risk reduction of total mortality in the IOWA women study(89), two 434 
studies from the Nurse's Health Study cohort found an effect on mortality only from a 435 
sudden cardiac event(90, 91).  Similarly, two studies from the Health Professional Study 436 
showed a risk reduction of myocardial infarction(92, 93). An interesting finding was the 437 
observation that there was a risk reduction by ALA when the EPA + DHA 438 
consumption was < 100 mg/day, and  that this effect was lost when EPA + DHA  439 
consumption was ≥ 100 mg/day with a significant interaction  (p = 0.003 for 440 
myocardial infarction and p = 0.006 for total CVD) between the two intakes. Similarly, 441 
the risk reduction observed for fatal IHD in a prospective study based on measurement 442 
of ALA in phospholipids was abolished after adjusting for EPA+DHA(94).  Two 443 
prospective studies based on ALA intake and conducted in Northern Europe, the 444 
ATBC study(95) and the Zutphen study(96) did not show any significant association.  445 
 446 
More recently, another study based on circulating and dietary ALA found  no effect of 447 
this fatty acid on congestive heart failure(97). In a meta-analysis published in 2012, 448 
 15
there was a borderline significant risk reduction for CVD, and only fatal CHD was 449 
significant (98). A large unexplained heterogeneity was present in this meta-analysis, 450 
casting doubts on the results. A more recent analysis using a pooled study design found 451 
a non-significant inverse association between ALA intake and CHD risk in men, but no 452 
consistent association in women(99). There has also been a report of a moderate non-453 
linear association of ALA with heart failure(100), and one showing no association of 454 
ALA with atrial fibrillation(101).  455 
 456 
Several studies have compared RO with OO on risk factors for CVD.  A hypoenergetic 457 
RO-containing diet (supplied as oil and margarine) reduced systolic blood pressure, 458 
and total and LDL cholesterol to a comparable extent as a refined OO diet, and also 459 
resulted in a greater reduction in diastolic blood pressure, probably because of the 460 
higher ALA content of the RO diet(102). In another study, RO resulted in a reduction of 461 
total cholesterol of 12%  versus 5.4% for OO, but HDL was also significantly reduced 462 
in the RO group, but not with OO(103). In a further study, 18 subjects in 6 experimental 463 
cross-over groups received 50g of oil / 10 MJ in a diet of 15 MJ. After three weeks, 464 
there was a significant reduction of LDL cholesterol in the RO group which is 465 
expected since RO contains 21% PUFAs(104). All other biomarkers were not 466 
significantly different. With the same study design, the same group later published 467 
results on TAG. After three weeks, fasting TAG were significantly higher for the OO 468 
regimen, with no difference on either post-prandial TAG nor on susceptibility to 469 
lipoprotein oxidation(105).  470 
 471 
In conclusion, despite limited evidence of benefits of RO in short term studies on 472 
biomarker risk factors for CVD, there are currently no observational and intervention 473 
studies to suggest that RO has the cardiovascular benefits of EVOO. Any benefits of 474 
RO are likely to be due to ALA. 475 
 476 
Cancer  477 
ALA has been associated with an increased risk of prostate cancer, but results are 478 
inconsistent. A meta-analysis did not find an association between dietary ALA intake 479 
and prostate cancer risk(106), although a more recent study has found that ALA 480 
increased the risk of advanced prostate cancer in elderly men(107) (Table 3). There are 481 
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indications of risk for gastric cancer(108). Inhalation of the vapours from unrefined RO 482 
with a high content of ALA used for cooking was associated to cancers in China(109). 483 
 484 
We did not conduct searches for the effects of RO on other diseases. 485 
 486 
Recent developments 487 
The increased susceptibility of ALA to oxidation has led to the commercial 488 
development of modified ROs with decreased ALA. These include a low linolenic acid 489 
canola oil (LLCO), which has an increased linoleic acid content, and a high oleic 490 
canola oil (HOCO)(15). These modified oils have better heat stability(37), but they are 491 
more expensive than standard RO. There are currently no clinical studies on their 492 
effects on health. However, as noted above, reducing ALA and increasing MUFA may 493 
reduce possible cardioprotective benefits of RO.   494 
 495 
A second approach has been to increase the level of antioxidant phytochemicals in RO. 496 
In 2006 the EU funded project "Optim'Oils" was initiated with the aim of improving 497 
production methods for RO. An oil with significantly lower 18:3 trans and improved 498 
phytochemical composition (minimised losses of phytosterols, tocopherols and 499 
phenolics) was successfully developed(17). In a clinical study, total-/HDL-cholesterol 500 
and LDL-/HDL-cholesterol were increased by 4% (p<0.05) with consumption of raw 501 
standard RO and there were also non-significant increases in ox-LDL. These increases 502 
were not seen with the optimised oil(110), and hence there were modest benefits of the 503 
optimised RO compared to the standard RO.  504 
 505 
Another interesting way forward is to incorporate olive phenolics into RO. The waste 506 
water from OO production (olive mill waste water, OMWW) contains high levels of 507 
some olive phenolics(111), and disposal of OMWW is of major environmental 508 
concern(112). An OMWW extract has been used to improve the oxidative stabilities of 509 
lard(113), sunflower oil(114) and refined OO(115). A seed oil comprising 30% high-oleic 510 
sunflower oil and 70% RO enriched with OMWW was found to reduce postprandial 511 
inflammation in obese subjects as effectively as VOO, even after 20 cycles of heating 512 
the oils at 180°C(34). Incorporation of phenolics from OMWW also has the potential to 513 
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improve the cardiovascular health benefits of RO since OMWW, which has high levels 514 
of hydroxytyrosol, has been shown to reduce LDL oxidation(116).  515 
 516 
Conclusions 517 
The extensive evidence for health benefits of EVOO is not matched by similar data for 518 
RO, and based on current evidence, RO cannot be recommended as equivalent in terms 519 
of health benefits compared to EVOO. There are significant losses of minor 520 
constituents during the processing of standard RO and there may also be deleterious 521 
changes in FA composition when RO is used for cooking. New initiatives to alter the 522 
production methods and composition of RO are addressing some of these issues and 523 
could lead to a far healthier, albeit more expensive, product for the consumer in the 524 
future. Nevertheless, RO lacks many of the constituents in EVOO, such as secoiridoids 525 
and derivatives, which are thought to be important for its health benefits and desirable 526 
stability during cooking. The use of OMWW to stabilise RO and improve its health 527 
benefits may be of mutual benefit to both industries by using an environmentally 528 
polluting waste product from the OO industry to the benefit of producing a healthier 529 
product for the RO industry. However, the current high fungicide usage on the oilseed 530 
rape crop is also of concern(117). 531 
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 Table 1 Compositions of Rapeseed Oil and Olive Oils 
 
 Rapeseed oil (15, 17) Olive oils (16) 
Main fatty acids (g/100g)   
Palmitic acid (16:0) 3.6 7.5 - 20.0 
Oleic acid (18:1) 61.6 55 - 83 
Linoleic acid (18:2) 21.7 3.5 - 21.0 
α-Linolenic acid (18:3) 9.6  0.0 - 1.0 
Minor components (g/kg)   
Squalene  0.28 0.7 - 12.0 
Carotenoids 0.01 0.001- 0.01 
Phytosterols  6.9 1.0 - 2.3 
Tocopherols  0.43 - 2.68 0.036 - 0.37 
Phenolics  0.05 0.05 - 0.8 
 
Table 2. Recent epidemiological studies on the health effects of olive oil  
 
Study Disease 
outcome 
Study 
design 
Subjects/cas
es 
Age range 
Olive oil 
type 
Exposure 
measurement 
Statistics 
adjustments 
Intake 
categorisation 
Relative Risk  
(95% CI) 
Trend 
Samieri et al, 
201151  
(Three-City 
study, 
France) 
Stroke Prospective  
Median 
follow-up 
5.25 years 
7 625/148  
≥ 65 years 
(37.7% 
males) 
Total OO Frequency of 
broad 
categories food 
and preferred 
added fat 
Cox model 
1-Age, sex, education, 
study centre 
2-Foods of the Med 
diet; other oils; animal 
fat; smoking; alcohol; 
PA; other stroke risk 
factors; BMI, TG, Total 
cholesterol 
Moderate 
(dressing or 
cooking), 
intensive users 
(dressing and 
cooking) versus 
no users 
Intensive users: 
0.59 (0.37, 0.94) 
0.02 
Bendinelli et 
al, 201152 
(EPICOR 
study, Italy) 
Myocardial 
infarction 
Prospective 
Follow-up 
average 
7.85 years 
29 689/144 
Women 35-
74 years 
Total OO Validated 
EPIC FFQ 
Cox model 
1-Energy 
2- education, fruit, 
vegetables, meat , 
smoking; alcohol body 
weight and waist 
circumference 
≥ 31.2 g/d 
versus ≤ 15.9 
g/d 
0.56 (0.31, 0.99) 0.04 
Buckland et 
al, 201253 
(EPIC-Spain) 
 
Overall and 
CVD 
mortality 
 
Prospective 
Follow-up 8 
to 12 years 
 
40 622/1 
915 deaths/ 
416 CVD 
Women 29-
69 years 
Total OO Validated 
dietary history 
questionnaire 
600 items 
Cox model 
1-Age, sex, study centre 
2-non-nutritional 
factors: BMI, waist 
circumference smoking; 
alcohol; PA 
3- Foods of the Med 
diet score 
29.4 g/d /8.4MJ 
versus < 
14.9 g/d /8.4MJ 
 
Overall 
mortality: 0.74 
(0.64, 0.87);  
CVD mortality 
0.56 (0.40, 0.79) 
 
 
 
<0.001 
 
<0.001 
Buckland et 
al, 201255 
(EPIC-Spain) 
 
CHD 
incidence 
Prospective 
Follow-up 8 
to 12 years 
40 142/587 
29-69 years 
(38% 
males) 
Total OO 
EVOO 
Validated 
dietary history 
questionnaire 
600 items 
Cox model 
1-Age, sex, study centre 
2-nonnutritional 
factors: BMI, waist 
circumference smoking; 
alcohol; PA 
3- Foods of the Med 
diet score, excluding 
olive oil and alcohol 
4- Goldberg exclusions 
≥28.9g versus 
<10g 
 
 
0.78 (0.59, 1.03) 
 
  
0.079 
Guasch-Ferré 
et al, 201456 
(PREDIMED
Spain) 
CVD events 
and 
mortality 
Prospective 
Follow-up 
4.8 years 
7 216 
subjects at 
risk for 
CVD/227 
events/323 
deaths; 67 ± 
6 (42% 
males) 
Total OO, 
non-virgin 
OO, EVOO 
Validated 
dietary history 
questionnaire 
137 items 
Cox model 
1-Age, sex, intervention 
group 
2-non-nutritional 
factors: BMI, waist 
circumference smoking; 
alcohol; PA; markers of 
risk factors 
3- Med diet score, 
excluding olive oil and 
alcohol 
 
Total OO: 56.9 
± 10 versus 
21.4 ± 8 g/d 
EVOO/ 34.6 ± 
27.4 versus 9.1 
± 11 g/d 
Non virgin OO: 
21.7 ± 25.1 
versus 12.1 ± 
11.7 g/d 
CV event total 
OO; 0.65 (0.47, 
0.91) 
EVOO 0.61 
(0.44, 0.85)  
Non-virgin OO: 
NS 
CV mortality 
total OO 0.52 
(0.73, 0.96)  
EVOO:NS 
OO: NS 
 
 
0.01 
 
<0.01 
 
 
 
 
0.04 
Buckland et 
al, 201271 
Spain, Italy, 
Greece 
Breast 
cancer 
Prospective 
9 year 
follow up 
 
62 284/1
256 cases 
Total OO Validated FFQ Cox model 
Age, education, 
reproductive factors 
fruit, vegetables, meat , 
smoking; alcohol body 
weight 
30.1 g/d versus 
11.1g/d 
0.77 (0.48, 
1.26) 
 
Berr et  al, 
200973 
Cognitive 
decline 
Prospective 
Median 
6 924 
65 to ≥80 
Total OO Frequency of 
broad 
Cox model 
0-Age, sex, education, 
No use versus 
intensive use 
Visual memory: 
0.83 (0.69, 
0.01 
(Three-City 
study, 
France) 
follow-up 4 
years 
years 
(39.7% 
males) 
categories food 
and preferred 
added fat 
centre, baseline 
cognitive 
1- health behaviours 
and health status; 2-
smoking and dietary 
habits 
0.99); Verbal 
fluency 0.85 
(0.70, 1.03) 
 
OO, olive oil; PA, physical activity; BMI, body mass index; TG, triglyceridaemia; Goldberg exclusion, exclusion of participants with poor 
concordance of energy intake to energy expenditure identified using Goldberg criteria 
Table 3. Epidemiological studies on the health effects of dietary α-linolenic acid 
 
Study Disease 
outcome 
Study design Subjects/cases 
Age range  
 
Exposure 
measurem
ent 
Statistics 
adjustments 
Intake 
categorisation 
Relative 
risk‡  
(95% CI) 
Trend 
Folsom et al 
200488 (Iowa 
women 
health study, 
USA) 
Total 
mortality  
Prospective 
Follow-up 14 
years 
41 836/4 653  
55-69 years 
FFQ 127 
items 
1) Age and energy and 2) 
covariates previously reported to 
be associated with total and CV 
mortality in this cohort  
1.21 versus 0.96  
g ALA/day 
(supplementary 
analysis) 
0.85  
(not 
given ) 
0.01 
Albert et al, 
200589 
(NHS, USA)  
SCD and 
other CHD 
Prospective  
Follow-up 18 
years 
76 763 
women/ 206 
SCD, 641 
other CHD 
deaths 
30-55 years 
 
Validated 
FFQ 
Alcohol, menopausal status, HRT, 
PA, aspirin, vitamin supplements,  
hypertension, 
hypercholesterolemia, diabetes, 
family history of MI and history 
of prior CVD, trans FA, ratio of 
PUFA to SFA and n-3 fatty acids 
0.74 versus 
0.31% TEI as 
ALA 
SCD 0.60 
(0.37–
0.96);  
Other 
outcomes 
NS 
 
0.02 
Hu et al, 
199990 
(NHS, USA) 
Fatal and 
non fatal 
IHD 
Prospective 
 
76 283 /232 
fatal /597 non 
fatal IHD  
30-55 years 
 
FFQ 116 
items 
Age, BMI, smoking, 
hypertension, diabetes, 
hypercholesterolaemia, 
menopausal status, HRT, parental 
history of MI, multiple vitamin 
use, alcohol , aspirin, PA, SFA, 
LA, vitamins C and E, total 
energy 
1.36  versus 
0.31 g ALA/d 
Fatal IHD 
0.55 (0.32, 
0.94); 
Non fatal 
IHD NS 
 
 
0.01 
Lemaitre et 
al, 201296 
(Cardiovascu
lar health 
Fatal and 
non-fatal 
IHD 
Prospective  
Follow–up 10 
years 
Dietary 
analyses 4 
432/1 072; 
Biomarkers 
FFQ with 
pictures 
Plasma 
concentrat
Age, sex, race, education, 
smoking status, BMI, waist 
circumference, alcohol 
consumption 
3.2 versus 1.4l 
ALA as % total 
fat intake; 
% total plasma 
Dietary 
and 
biomarker 
NS  
 
study) 
 
2 957/686 
 
ion FA 
concentration  
Vedtofte et 
al, 201498 
Incident 
CHD fatal 
and non-
fatal 
Pooled 
analysis of 11 
prospective 
cohorts 
(criteria: 
≥150 
outcomes and 
validated 
FFQ or diet 
record) 
Follow-up 4–
10 years   
229 043 /4 493 
CHD events 
and 1 751 
CHD deaths  
FFQ or 
diet record 
BMI, education, smoking, PA, 
alcohol, total energy intake, SFA, 
trans FA, MUFA, LA, n-3 LC 
PUFA, dietary fibre, hypertension 
 
women 1.64 
versus 0.58 g 
ALA/d; men 
1.62 versus 1.17  
g ALA/d 
Men: 
CHD 
event 0.85 
(0.72, 
1.01); 
CHD 
death 0.77 
(0.58, 
1.01). 
Women: 
CHD NS; 
CHD 
death NS 
0.07§ 
Ascherio et 
al, 199691,  
(HPFUS) 
Incidence 
of acute 
MI or 
coronary 
death 
Prospective  
Follow-up 6 
years 
3 757/ 734 MI 
/229 deaths 
40-75 years  
Validated 
FFQ 131 
items 
Age, BMI, smoking,  PA, alcohol, 
hypertension, cholesterol, family 
history of MI, fibre intake, energy 
 
1.5 versus 0.8  g 
ALA/d; 1% 
energy 
increase/d 
MI 0.80 
(0.63 to 
1.03) 
Death NS; 
MI 
0.41(0.21- 
0.80) 
Death NS 
0.07 
Mozaffarian 
et al, 200592 
CHD Prospective 
HPFUS 
Follow-up 14 
years 
45 722/ 2 306 
total CHD/ 218 
sudden deaths/ 
1521 nonfatal 
MI  
40-75 years 
Validated 
FFQ 131 
items 
Age, BMI, smoking,  PA, alcohol, 
hypertension, cholesterol, family 
history of MI, diabetes, aspirin 
use, protein, SFA, fibre, MUFA, 
trans FA, energy, n-6 fatty acids, 
EPA+DHA, 
1g ALA/ d + 
<100mg 
EPA+DHA 
 
 
 
 
Non fatal 
MI 0.42 
(0.23-
0.75) 
Total 
CHD 0.53 
(0.34-
 
1g ALA/d + 
≥100mg 
EPA+DHA 
 
0.83) 
Death NS 
 
NS 
Lemaitre et 
al, 200393 
Fatal and 
non fatal 
IHD 
Case-control 
nested in 
Prospective 
Cardiovascul
ar Health 
Study, 
Follow-up 3 
years 
179 controls/ 
54 fatal (male 
58%)/125 non 
fatal (male 
64%) 
≥65 years 
Plasma 
measurem
ents 
Age, study centre, sex, smoking, 
alcohol, TAG, HDL-cholesterol, 
hypertension, diabetes, congestive 
heart failure, claudication, heart 
rate, family history of MI, 
fibrinogen, PA. Analyse on 
combined PUFAs 
1 SD increase in 
plasma 
concentration of 
ALA 
NS for 
fatal and 
non fatal 
 
Pietinen et 
al, 199794  
(ATBC 
cohort, 
Finland) 
CHD Prospective 
Follow-up 6  
years 
21 930/1 399 
events/633 
deaths 
Validated 
FFQ 276 
items 
Age, supplement, group 
several coronary risk factors, total 
energy and fibre intake 
2.5 versus 0.9  g 
ALA/d 
NS  
Oomen et al, 
200195 
(Zutphen 
elderly 
cohort) 
Coronary 
artery 
disease 
Prospective 
 
667/98 Cross-
check, 
dietary 
history 
method 
Age, standard coronary risk 
factors, and intake of trans fatty 
acids and other nutrients, 
≥ 0.58 versus 
<0.45 % energy 
intake as ALA 
NS  
Wilk et al, 
201299 
(Physician's 
Health study) 
Heart 
failure 
Prospective , 
nested case-
control.  
19 097/1 572 Plasma 
measurem
ents and 
validated 
FFQ 
Age at time of blood sampling, 
atrial fibrillation, hypertension, 
BMI, alcohol, smoking,  
Plasma ALA 
concentration 
0.306 versus 
0.097  total % 
FA. Dietary  
ALA versus 
0.576 g/d 
Plasma Q4 
0.66 (0.47, 
0.94); Q5 
NS; 
Dietary 
NS 
 
‡ when nested case-control study; § p for sex interaction 
ALA, α-linolenic acid; HPFUS, Health Professional Follow-up study; HRT, hormone replacement therapy; IHD, ischaemic heart disease; LA, 
linoleic acid; LC, long chain; MI, myocardial infarction; NHS, Nurse's Health Study; NIH-AARP National Institute of Health Aged American 
Retired Persons; PA, physical activity; PSA, prostate specific antigen; Q, quintile; SD, standard deviation; SCD, sudden cardiac death; SFA, 
saturated fatty acids; TEI, total energy intake 
 
Fretts et al, 
2013100 
(Cardiovascu
lar Health 
Study, USA) 
Incident 
atrial 
fibrillation 
Prospective 4 337 
≥ 65 years 
Plasma 
measurem
ents and 
validated 
FFQ, 131 
items 
Age, sex (and total calorie intake 
for dietary analyses), race, 
education, smoking, history of 
heart failure, history of stroke, 
BMI, waist circumference, PA, 
hypertension, LA (for plasma 
measurements) 
0.21 versus 
0.10 % total FA, 
Plasma 
NS 
Dietary 
NS  
NS 
NS 
Pelser et al, 
2013106  
(NIH-AARP, 
USA) 
Prostate 
cancer 
Prospective 
Follow-up 9 
years 
288 268/23 
281 
(18 934 non-
advanced/ 2 
930 advanced/ 
725 fatal) 
50-71 years 
Validated 
FFQ, 124 
items 
Age, race, family history, marital 
status, education, diabetes, PSA 
screening, total energy, alcohol, 
tomatoes, BMI in 3 levels (<25, 
25 to <30, and 30 kg/m2 and 
above), PA, smoking  
% energy 0.41 
versus 0.88 
Non 
advanced 
NS 
Advanced 
1.17 (1.04, 
1.3)  
0.01 
Chajes et al, 
2011107  
(EPIC)  
Gastric 
adeno-
carcinoma 
Prospective 
Nested in the 
cohort 
626/238  
43 to 72 years 
Plasma 
concentrat
ion 
H. pylori infection, BMI, 
smoking, PA, education, 
socioeconomic status, energy 
intake 
ALA ≥0.24 
versus <0.13 
as % of total 
fatty acids 
 
3.20 (1.70, 
6.06) 
0.001 
